Drugs / Sipuleucel-T
Sipuleucel-T
Trials 24 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 15 trials | ||||||
| Phase 1 | NCT07219147 | Mar 2026 → Jul 2028 expected | prostate adenocarcinoma | City of Hope Medical Center | Recruiting | No outcome recorded |
| Phase 1 | NCT05806814 | Nov 2023 → May 2026 overdue | castration-resistant prostate carcinoma | University of Oklahoma | Active not recruiting | No outcome recorded |
| Phase 1 | NCT03024216 | Feb 2017 → Dec 2020 | metastatic prostate carcinoma | University of Hawaii | Completed | No outcome recorded |
| Phase 1 | NCT02036918 | Mar 2014 → Feb 2019 | prostate cancer | Duke University | Completed | No outcome recorded |
| Phase 1 | NCT01832870 | Apr 2013 → Feb 2016 | castration-resistant prostate carcinoma | Prostate Oncology Specialists, Inc. | Completed | No outcome recorded |
| Phase 217 trials | ||||||
| Phase 2 | NCT06100705 | Dec 2023 → Dec 2027 expected | prostate carcinoma | Yale University | Recruiting | No outcome recorded |
| Phase 2 | NCT06134232 | Oct 2023 → Dec 2031 expected | castration-resistant prostate carcinoma | Dendreon | Recruiting | No outcome recorded |
| Phase 2 | NCT02793765 | Dec 2016 → Jul 2018 | prostate cancer | The University of Texas Health Science Center, Houston | Withdrawn | No outcome recorded |
| Phase 2 | NCT02793219 | Dec 2016 → Jul 2018 | prostate cancer | The University of Texas Health Science Center, Houston | Withdrawn | No outcome recorded |
| Phase 2 | NCT02463799 | Feb 2016 → Dec 2019 | prostate cancer | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Completed | No outcome recorded |
| Phase 2 | NCT02159950 | Jan → Jul 2015 | hormone-resistant prostate carcinoma, metastatic prostate carcinoma | Roswell Park Cancer Institute | Completed | No outcome recorded |
| Phase 2 | NCT01981122 | Sep 2013 → Jun 2017 | metastatic prostate carcinoma | Dendreon | Completed | No outcome recorded |
| Phase 2 | NCT01818986 | Jul 2013 → Dec 2019 | prostate carcinoma | University of Texas Southwestern Medical Center | Completed | No outcome recorded |
| Phase 2 | NCT01807065 | Jun 2013 → Dec 2018 | hormone-resistant prostate carcinoma, malignant soft tissue neoplasm, metastatic carcinoma in the bone, prostate adenocarcinoma | City of Hope Medical Center | Completed | No outcome recorded |
| Phase 2 | NCT01706458 | May 2013 → Jun 2017 | prostate cancer | University of Wisconsin, Madison | Completed | No outcome recorded |
| Phase 2 | NCT01477749 | Jun 2012 → Jun 2014 | prostate cancer | Dendreon | Completed | No outcome recorded |
| Phase 2 | NCT01338012 | Dec 2011 → Apr 2015 | prostate cancer | Dendreon | Terminated | No outcome recorded |
| Phase 2 | NCT01487863 | Dec 2011 → May 2016 | castration-resistant prostate carcinoma, hormone-resistant prostate carcinoma, metastatic prostate carcinoma | Dendreon | Completed | No outcome recorded |
| Phase 2 | NCT01431391 | Sep 2011 → Dec 2014 | prostate adenocarcinoma | Dendreon | Completed | No outcome recorded |
| Phase 2 | NCT00901342 | Oct 2009 → Dec 2014 | prostate cancer | Dendreon | Completed | No outcome recorded |
| Phase 2 | NCT00715104 | Jul 2008 → Dec 2012 | prostate cancer | Dendreon | Completed | No outcome recorded |
| Phase 2 | NCT00027599 | Dec 2001 → Jul 2007 | prostate cancer | National Cancer Institute (NCI) | Completed | No outcome recorded |
| Phase 32 trials | ||||||
| Phase 3 | NCT03686683 | Oct 2018 → Mar 2023 | prostate adenocarcinoma | Dendreon | Completed | No outcome recorded |
| Phase 3 | NCT00779402 | Oct 2001 → Aug 2006 | prostate cancer | Dendreon | Completed | No outcome recorded |
Also used as a comparator or background therapy in 7 trials
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 24 trials | ||||||
| Phase 2 | NCT05751941 Background | Feb 2023 → Jul 2026 overdue | metastatic prostate carcinoma | H. Lee Moffitt Cancer Center and Research Institute | Active not recruiting | No outcome recorded |
| Phase 2 | NCT01804465 Background | Apr 2014 → Feb 2020 | prostate cancer | University of California, San Francisco | Completed | No outcome recorded |
| Phase 2 | NCT01560923 Background | Oct 2012 → Dec 2018 | metastatic prostate carcinoma | Masonic Cancer Center, University of Minnesota | Completed | No outcome recorded |
| Phase 2 | NCT00715078 Comparator | Oct 2008 → Apr 2012 | prostate cancer | Dendreon | Completed | No outcome recorded |
| Phase 33 trials | ||||||
| Phase 3 | NCT00065442 Comparator | Jul 2003 → Jan 2009 | prostate cancer | Dendreon | Completed | No outcome recorded |
| Phase 3 | NCT01133704 Comparator | May 2000 → Mar 2003 | hormone-resistant prostate carcinoma | Dendreon | Completed | No outcome recorded |
| Phase 3 | NCT00005947 Comparator | Nov 1999 → Sep 2004 | prostate cancer | Dendreon | Completed | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 31 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Sipuleucel-T | “Sipuleucel-T is a US Food and Drug Administration-approved autologous cellular immunotherapy that improves survival in patients with metastatic castration-resistant prostate...” PMID 33986125 ↗ May 202130 |
| Known as | APC8015 | “sipuleucel-T (APC8015)” NCT01133704 ↗ |
| Known as | Provenge | “Those enrolled in the Booster Study will have had their course of treatment with PROVENGE® immunotherapy and then randomized to the Booster Study to be treated with a single...” NCT06134232 ↗2“An Open Label, Phase 2 Trial of Immunotherapy With Sipuleucel-T (Provenge®) as Neoadjuvant Treatment in Men With Localized Prostate Cancer” NCT00715104 ↗ “Immunotherapy With APC8015 (Sipuleucel-T, Provenge) for Asymptomatic, Metastatic, Hormone-Refractory Prostate Cancer” NCT01133704 ↗ |
| Action | Deplete | “they may stimulate T cells to kill prostate tumor cells.” NCT07219147 ↗ |
| Modality | Cell therapy | “Autologous peripheral blood mononuclear cells, including antigen presenting cells, that have been activated in vitro with a recombinant fusion protein, PAP-GM-CSF.” NCT00005947 ↗ |
| Route | Intravenous | “Patients receive APC8015 comprised of ADCP activated with prostatic acid phosphatase-sargramostim (GM-CSF) fusion protein IV over 30 minutes” NCT00005947 ↗ |